ArticleBMC pregnancy and childbirth2025
Exploring the potential of cell-free RNA and Pyramid Scene Parsing Network for early preeclampsia screening.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Machine Learning Prediction Models for Preeclampsia: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
- Artificial Intelligence for the Prediction of Preeclampsia: Current Evidence, Comparison with Conventional Screening Models, and Future Perspectives.Diagnostics (Basel, Switzerland) · 2026Review
- Correction: Exploring the potential of cell‑free RNA and pyramid scene parsing network for early preeclampsia screening.BMC pregnancy and childbirth · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
backgroundCirculating cell-free RNA (cfRNA) is gaining recognition as an effective biomarker for the early detection of preeclampsia (PE). However, the current methods for selecting disease-specific biomarkers are often inefficient and typically one-dimensional. PURPOSE: This study introduces a Pyramid Scene Parsing Network (PSPNet) model to predict PE, aiming to improve early risk assessment using cfRNA profiles.
methodsThe theoretical maximum Preeclamptic Risk Index (PRI) of patients clinically diagnosed with PE is defined as "1", and the control group (NP) is defined as "0", referred to as the clinical PRI. A data preprocessing algorithm was used to screen relevant cfRNA indicators for PE. The cfRNA expression profiles were obtained from the Gene Expression Omnibus (GSE192902), consisting of 180 normal pregnancies (NP) and 69 preeclamptic (PE) samples, collected at two gestational time points: ≤ 12 weeks and 13-20 weeks. Based on the differences in cfRNA expression profiles, the Calculated Ground Truth values of the NP and PE groups in the sequencing data were acquired (Calculated PRI). The differential algorithm was embedded in the PSPNet neural network and the network was then trained using the generated dataset. Subsequently, the real-world sequencing dataset was used to validate and optimize the network, ultimately outputting the PRI values of the healthy control group and the PE group (PSPNet-based PRI). The model's predictive ability for PE was evaluated by comparing the fit between Calculated PRI (Calculated Ground Truth) and PSPNet-based PRI.
resultsThe mean absolute error (MAE) between the Calculated Ground Truth the PSPNet-based PRI was 0.0178 for cfRNA data sampled at ≤ 12 gws and 0.0195 for data sampled at 13-20 gws. For cfRNA data sequenced at ≤ 12 gws and 13-20 gws, the corresponding loss values, maximum absolute errors, peak-to-valley error values, mean absolute errors, and average prediction times per sample were 0.0178 (0.0195).
conclusionsThe present PSPNet model is reliable and fast for cfRNA-based PE prediction and its PRI output allows for continuous PE risk monitoring, introducing an innovative and effective method for early PE prediction. This model enables timely interventions and better management of pregnancy complications, particularly benefiting densely populated developing countries with high PE incidence and limited access to routine prenatal care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.